» Authors » Lesley C Dupuy

Lesley C Dupuy

Explore the profile of Lesley C Dupuy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 368
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Dupuy L, Spiropoulou C, Towner J, Spengler J, Sullivan N, Montgomery J
J Infect Dis . 2023 Oct; 228(Suppl 6):S446-S459. PMID: 37849404
Viruses in the family Filoviridae, including the commonly known Ebola (EBOV) and Marburg (MARV) viruses, can cause severe hemorrhagic fever in humans and nonhuman primates. Sporadic outbreaks of filovirus disease...
2.
Suschak J, Dupuy L, Shoemaker C, Six C, Kwilas S, Spik K, et al.
Mol Ther Methods Clin Dev . 2020 Apr; 17:810-821. PMID: 32296729
DNA vaccines expressing codon-optimized Venezuelan equine encephalitis virus (VEEV) and Ebola virus (EBOV) glycoprotein genes provide protective immunity to mice and nonhuman primates when delivered by intramuscular (IM) electroporation (EP)....
3.
Ricks K, Shoemaker C, Dupuy L, Flusin O, Voorhees M, Fulmer A, et al.
J Virol Methods . 2019 Apr; 270:12-17. PMID: 30998959
There is a pressing need for sustainable and sensitive immunodiagnostics for use in public health efforts to understand and combat the threat of endemic and emerging infectious diseases. In this...
4.
Samsa M, Dupuy L, Beard C, Six C, Schmaljohn C, Mason P, et al.
Mol Ther . 2019 Feb; 27(4):850-865. PMID: 30770173
Venezuelan equine encephalitis virus (VEEV) is a known biological defense threat. A live-attenuated investigational vaccine, TC-83, is available, but it has a high non-response rate and can also cause severe...
5.
Rusnak J, Dupuy L, Niemuth N, Glenn A, Ward L
Comp Med . 2018 Oct; 68(5):380-395. PMID: 30282570
Licensure of medical countermeasure vaccines to protect against aerosolized Venezuelan equine encephalitis virus (VEEV) requires the use of the Animal Rule to assess vaccine efficacy, because human studies are not...
6.
Suschak J, Bagley K, Six C, Shoemaker C, Kwilas S, Spik K, et al.
Antiviral Res . 2018 Oct; 159:113-121. PMID: 30268913
We have previously shown that DNA vaccines expressing codon-optimized alphavirus envelope glycoprotein genes protect both mice and non-human primates from viral challenge when delivered by intramuscular electroporation (IM-EP). To determine...
7.
Suschak J, Bagley K, Shoemaker C, Six C, Kwilas S, Dupuy L, et al.
J Infect Dis . 2018 Jul; 218(suppl_5):S519-S527. PMID: 30053157
In previous studies, we showed that deoxyribonucleic acid (DNA) vaccines expressing codon-optimized filovirus envelope glycoprotein genes protect mice and nonhuman primates from viral challenge when delivered by intramuscular (IM) electroporation...
8.
Dupuy L, Richards M, Livingston B, Hannaman D, Schmaljohn C
J Immunol Res . 2018 Jul; 2018:8521060. PMID: 29967804
There remains a need for vaccines that can safely and effectively protect against the biological threat agents Venezuelan (VEEV), western (WEEV), and eastern (EEEV) equine encephalitis virus. Previously, we demonstrated...
9.
Ripoll D, Mitchell D, Dupuy L, Wallqvist A, Schmaljohn C, Chaudhury S
Hum Vaccin Immunother . 2017 Sep; 13(12):2953-2966. PMID: 28922082
Ebola virus (EBOV) infection is highly lethal and results in severe febrile bleeding disorders that affect humans and non-human primates. One of the therapeutic approaches for treating EBOV infection focus...
10.
Mitchell D, Dupuy L, Sanchez-Lockhart M, Palacios G, Back J, Shimanovskaya K, et al.
Hum Vaccin Immunother . 2017 Jul; 13(12):2883-2893. PMID: 28699812
We performed epitope mapping studies on the major surface glycoprotein (GP) of Ebola virus (EBOV) using Chemically Linked Peptides on Scaffolds (CLIPS), which form linear and potential conformational epitopes. This...